All In Biotech

Drug Trial Radar · NCT05224141

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)

Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

460

Actual

Start

Mar 24, 2022

Primary completion

Jun 4, 2024

Study completion Jun 7, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.

Conditions

  • Small Cell Lung Carcinoma

Interventions

  • Pembrolizumab/Vibostolimab Co-FormulationBiological

    Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.

  • Saline placeboDrug

    Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)

  • EtoposideDrug

    Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles

  • CisplatinDrug

    Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.

  • AtezolizumabBiological

    Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.

  • CarboplatinDrug

    Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 25 months

Locations

140 sites in 25 countries. Site status is shown where the registry gives one.

  • Infirmary Cancer Care ( Site 0022)

    Mobile, Alabama

  • Los Angeles Hematology Oncology Medical Group ( Site 0006)

    Los Angeles, California

  • VA West Los Angeles Medical Center ( Site 0004)

    Los Angeles, California

  • Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014)

    Boca Raton, Florida

  • Fort Wayne Medical Oncology and Hematology ( Site 0013)

    Fort Wayne, Indiana

  • Dana-Farber Cancer Institute ( Site 0018)

    Boston, Massachusetts

  • Cancer and Hematology Centers of Western Michigan ( Site 0001)

    Grand Rapids, Michigan

  • Hattiesburg Clinic Hematology/Oncology ( Site 0003)

    Hattiesburg, Mississippi

  • Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0005)

    Lancaster, Pennsylvania

  • Blue Ridge Cancer Care ( Site 0015)

    Blacksburg, Virginia

  • University of Virginia Cancer Center ( Site 0019)

    Charlottesville, Virginia

  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0203)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201)

    Mar del Plata, Buenos Aires, Argentina

  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0200)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Hospital Provincial del Centenario ( Site 0205)

    Rosario, Santa Fe Province, Argentina

  • Sanatorio Parque ( Site 0202)

    Rosario, Santa Fe Province, Argentina

  • Nepean Hospital ( Site 2700)

    Kingswood, New South Wales, Australia

  • Calvary Mater Newcastle ( Site 2703)

    Waratah, New South Wales, Australia

  • Frankston Hospital-Oncology and Haematology ( Site 2702)

    Frankston, Victoria, Australia

  • Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 2701)

    Melbourne, Victoria, Australia

  • Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 0502)

    Vienna, Austria

  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0501)

    Vienna, Austria

  • Medizinische Universität Graz ( Site 0504)

    Graz, Styria, Austria

  • Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0505)

    Linz, Upper Austria, Austria

  • Kepler Universitätsklinikum ( Site 0507)

    Linz, Upper Austria, Austria

  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0106)

    Kingston, Ontario, Canada

  • Lakeridge Health ( Site 0102)

    Oshawa, Ontario, Canada

  • Anhui Cancer Hospital ( Site 2915)

    Hefei, Anhui, China

  • Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2901)

    Beijing, Beijing Municipality, China

  • Beijing Peking Union Medical College Hospital ( Site 2921)

    Beijing, Beijing Municipality, China

  • Fujian Provincial Cancer Hospital-oncology department ( Site 2904)

    Fuzhou, Fujian, China

  • Harbin Medical University Cancer Hospital-oncology of department ( Site 2920)

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital ( Site 2916)

    Zhengzhou, Henan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2912)

    Wuhan, Hubei, China

  • Hubei Cancer Hospital ( Site 2922)

    Wuhan, Hubei, China

  • Hunan Cancer Hospital ( Site 2907)

    Changsha, Hunan, China

  • The First Affiliated Hospital of Soochow University ( Site 2913)

    Suzhou, Jiangsu, China

  • Jilin Cancer Hospital-GCP office ( Site 2909)

    Changchun, Jilin, China

  • The First Hospital of Jilin University ( Site 2914)

    Changchun, Jilin, China

  • The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 2910)

    Xi'an, Shaanxi, China

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.